TD Asset Management INC increased the percentage of its holdings in 10x Genomics, INC (NASDAQ: TXG) during the third quarter by 124.0%, as stated in the most recent Form 13F filing that the company submitted with the SEC.
The organization finally reached a point where it owned 130,248 shares of the company’s stock after making additional purchases of 72,100 shares during the period above.
The most recent filing with the SEC reveals that TD Asset Management INC held 0.12% of 10x Genomics, which had a value of $3,898,000 at the time of the filing.
Several other hedge funds have recently revised their strategies to remain competitive in this industry.
The percentage of 10x Genomics stock that SRS Investment Management LLC held went up by 1,214.3% during the second quarter of the year. SRS Investment Management LLC now has 2,758,245 shares after purchasing an additional 2,548,380 shares during the quarter.
The stock is valued at a combined total of $124,811,000 due to the ownership of all these shares. FMR LLC’s holdings in 10x Genomics saw a total increase of 50.2% thanks to the company’s investment during the second quarter. FMR LLC now has 6,195,527 shares of the company’s stock, valued at $280,347,000, after purchasing an additional 2,070,318 shares during the period in question.
BlackRock INC increased the amount of 10x Genomics stock owned by 14.2% during the first three months of 2018.
BlackRock INC now owns 9,156,992 shares of the company’s stock, which has a value of $696,572,000 following the acquisition of an additional 1,138,358 shares during the most recent period.
This brings the total number of shares owned by BlackRock INC to 9,156,992.
Baillie Gifford & Co increased the 10x Genomics stock held by 13.9% over the second quarter.
Baillie Gifford & Co now has a total of the company’s stock worth $8,378,971 after purchasing an additional 1,023,207 shares of the company’s stock throughout the period in question.
Last but certainly not least, ARK Investment Management LLC increased the percentage of 10x Genomics shares it owned by 27.0 percent during the third quarter.
ARK Investment Management LLC has a total of 4,576,814 shares of the company’s stock, which have a value of $130,348,000 following the purchase of an additional 973,528 shares during the period in question.
These shares have a total value of $130,348,000. Shares of the company are currently held by various institutional investors, including hedge funds, which account for 74.34% of the total.
NASDAQ: TXG was first available for trading on Monday with an opening price of $47.84.
The previous year saw 10x Genomics, INC experience a range with a high of $99.14 and a low of the same value.
The stock’s moving average over the previous 50 days is $39.60, while the moving average over the previous 200 days is $35.99.
Recent times have seen the company receive feedback from various equity research analysts who have followed the company’s progress. JPMorgan Chase & Co announced, in a research note published on November 3, that they would be lowering their price objective for 10x Genomics from $65.00 to $55.00.
The previous price objective was $65.00.
The Goldman Sachs Group rated the stock as a “sell” and decreased their price objective for 10x Genomics from $35.00 to $25.00 in a report distributed on Thursday, October 13.
The first report that Deutsche Bank Aktiengesellschaft has produced regarding its coverage of 10x Genomics was made public on December 13 of this year.
They determined a price target of $50 for the stock and rated it as a “buy,” indicating that investors should purchase the stock.
Morgan Stanley lowered their target price for 10x Genomics from $70.00 to $65.00 while maintaining their “overweight” rating on the stock in a research report made available on Friday, November 4.
In a report made public on Thursday, the UBS Group announced that they have begun covering 10x Genomics.
They assigned a “neutral” rating to the stock and predicted it would trade between $45.00 and $50.00. Six market analysts have recommended purchasing the company’s stock, two have suggested investors maintain their current holdings, and two have suggested investors exit the market entirely.
The website Bloomberg.com suggests that investors “hold” their positions in 10x Genomics, and the website also indicates that the typical price target for the company is $50.90.
On Tuesday, November 22, Benjamin J. Hindson, an insider at 10x Genomics, sold 2,361 shares.
This information relating to 10x Genomics was discussed in other recent news articles.
The stock sale resulted in total revenue of $80,439, with the average share price being $34.07.
The company insider currently possesses 217,713 shares, which have a combined market value of $7,417,481.91. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail. On Tuesday, November 22, Benjamin J. Hindson, an insider at 10x Genomics, sold 2,361 shares.
This information relating to 10x Genomics was discussed in other recent news articles.
The stock sale resulted in total revenue of $80,439, with the average share price being $34.07.
The company insider currently possesses 217,713 shares, which have a combined market value of $7,417,481.91.
Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail.
Additionally, on November 22, 1,626 shares of the company’s stock were sold by Justin J.
Mcanear, who is the company’s CFO.
Mcanear disposed of these shares.
It was determined that the shares were sold at an average price of $34.07 each, which resulted in a total sale amount of $55,397.82. Following the conclusion of the transaction, the chief financial officer now directly owns 76,764 shares of the company.
Based on the current stock price, these shares are estimated to be worth approximately $2,615,349.48.
The disclosure about the purchase can be found in this particular location. Over the past three months, company insiders have offloaded 6,663 shares of company stock, resulting in a total sale volume of $227,008.
Employees and other company insiders hold an ownership stake of 11.08% of the company’s total shares.
The company’s primary mission is to develop hardware, software, and other resources to analyze biological systems and market these products across North America, Europe, the Middle East, Africa, China, and the Asia Pacific region.
Life science technology is the area of expertise of the company that goes by the name 10x Genomics, INC Aside from chromium and chromium connect devices; the company offers a wide range of other consumables such as microfluidic chips, slides, reagents, and many more.
Leave a comment